Alyeska Investment Group
INAB icon

Alyeska Investment Group’s IN8bio INAB Stock Holding History

Alyeska Investment Group’s Portfolio INAB Stock Details INAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-27,322
Closed -$1.13M – 535
2023
Q4 		$1.13M Buy
+27,322
New +$873K 0.01% 404

Other funds holding INAB

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Alyeska Investment Group's INAB Position: Q1 2026 in Review

Alyeska Investment Group reduced its IN8bio (INAB) stake by 1.4% in Q1 2026, selling an estimated $25.5K and leaving 944,319 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #561.

Alyeska Investment Group first reported a position in INAB in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.23M in Q4 2025. 19 funds tracked by Wall St. Rank hold INAB as of Q1 2026.

  • Alyeska Investment Group held 944,319 shares of IN8bio worth $1.4M as of Q1 2026.
  • Alyeska Investment Group sold 13,165 IN8bio shares in Q1 2026, an estimated $25.5K.
  • IN8bio made up ﹤0.01% of Alyeska Investment Group's portfolio in Q1 2026, its #561 holding.
  • Alyeska Investment Group first reported a position in IN8bio in Q4 2023 and has held it in 10 quarters since.
  • Alyeska Investment Group's IN8bio position peaked at $2.23M in Q4 2025.
  • 19 funds tracked by Wall St. Rank held IN8bio as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.